TABLE 4.

Differential response of the kas operon to isoniazid, thiolactomycin, or triclosan treatment

Treatmenta and timefabDacpMkasAkasBaccD6
RatiobP valueRatioP valueRatioP valueRatioP valueRatioP value
5×-MIC INH, 2 h1.533.06 × 10−43.15<1.00 × 10−462.812.78 × 10−292.781.49 × 10−28NS
5×-MIC INH, 6 h2.27<1.00 × 10−464.53<1.00 × 10−464.401.87 × 10−313.54<1.00 × 10−46NS
1×-MIC TLM, 2 h2.261.54 × 10−44.30<1.00 × 10−463.794.77 × 10−153.421.09 × 10−181.691.12 × 10−11
5×-MIC TLM, 2 hNS3.70<1.00 × 10−462.947.92 × 10−202.081.43 × 10−61.418.06 × 10−5
1×-MIC TLM, 6 h1.889.48 × 10−63.01<1.00 × 10−462.875.33 × 10−392.108.86 × 10−101.418.36 × 10−4
5×-MIC TLM, 6 h1.795.01 × 10−64.00<1.00 × 10−462.934.49 × 10−372.411.61 × 10−14NS
5×-MIC TRC, 2 hNS0.243.30 × 10−240.308.29 × 10−150.366.27 × 10−9NS
5×-MIC TRC, 6 hNS0.13<1.00 × 10−460.20<1.00 × 10−460.345.37 × 10−25NS
  • a INH, isoniazid; TLM, thiolactomycin; TRC, triclosan.

  • b Average expression ratio (drug treated/t = 0 control) calculated from a total of four hybridizations of two biological replicates. NS, not significant (P < 0.001).